CIK 0001885522
- Non-accelerated filer
- Smaller reporting company
Neumora Therapeutics, Inc.
Sign in to watch- Ticker
- NMRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 844367680
- Phone
- +1 857-760-0900
- Business address
- 260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
- 4 Grant or award Director acquired 20,100 shares (grant or award)
- 4 Grant or award Director acquired 20,100 shares (grant or award)
- 4 Grant or award Director acquired 20,100 shares (grant or award)
- 4 Grant or award Director acquired 20,100 shares (grant or award)
- 4 Grant or award Director acquired 20,100 shares (grant or award)
- 4 Gift Chief Strategy Officer gave 114,703 shares (gift)
- 4 Grant or award Chief Financial Officer acquired 85,000 shares (grant or award)
- 4 Grant or award Chief Strategy Officer acquired 97,500 shares (grant or award)
- 4 Grant or award Chief Operating Officer acquired 85,000 shares (grant or award)
- 4 Grant or award Director acquired 171,250 shares (grant or award)
- 4 Grant or award President & CEO acquired 80,000 shares (grant or award)
- 4 Grant or award Milligan Michael Lee acquired 20,625 shares (grant or award)
- 4 Grant or award Head of R&D acquired 50,000 shares (grant or award)
- 4 Other acquisition 10% owner acquired 1,879,654 shares (other)
- 4 Other acquisition 10% owner acquired 1,879,654 shares (other)
- 4 Other acquisition Director acquired 1,893,651 shares (other)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 35,010 shares at an average $11.77 ($412,140)
- 4 Open-market buy 10% owner bought 35,010 shares at an average $11.77 ($412,140)
Page 4 of 6 · 118 filings